CHRNB3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1008491	0.61	20/20
SCHEMBL1404444	0.61	20/20
Hydrochloric Acid (SCHEMBL741789)	0.59	20/20
SCHEMBL1588528	0.53	19/20
SCHEMBL745221	0.78	16/20
Hydrochloric Acid (SCHEMBL745115)	0.75	16/20
SCHEMBL994561	0.53	12/20
SCHEMBL1283154	0.43	11/20
SCHEMBL559942	0.48	9/20
SCHEMBL559943	0.48	9/20
SCHEMBL676032	1.00	6/20
Fumaric Acid (SCHEMBL237911)	0.80	6/20
Fumaric Acid (SCHEMBL237912)	0.80	6/20
SCHEMBL1711180	0.61	6/20
SCHEMBL1711532	0.61	6/20
SCHEMBL1711592	0.61	6/20
SCHEMBL400513	0.48	6/20
SCHEMBL608991	0.48	6/20
SCHEMBL1712010	0.42	6/20
SCHEMBL905212	1.00	5/20

Clinical trials — most relevant to CHRNB3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING)	PHASE4	COMPLETED
Galantamine for Cognition in People With Schizophrenia	PHASE4	COMPLETED
Dexmedetomidine Effect on Delirium of Elderly Patients	PHASE4	UNKNOWN
Transcranial Magnetic Stimulation in Patients with Dual Disorders	PHASE3	NOT_YET_RECRUITING
Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3	PHASE2	COMPLETED
Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3])	PHASE2	COMPLETED
Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition	PHASE2	RECRUITING
Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
Social Cognition,Attentional Network and Nicotine Drug Dependency - A Pharmacological Clinical Trail	PHASE1/PHASE2	COMPLETED
Nicotinic Receptor Augmentation of SSRI Antidepressants	PHASE2	COMPLETED
Brain Networks and Addiction Susceptibility	PHASE1	COMPLETED
Nicotinic Receptor Genetic Variation and Alcohol Reward	PHASE1	RECRUITING
Gene Therapy for Alzheimer's Disease Clinical Trial	PHASE1	COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals	PHASE1	COMPLETED
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia	nan	UNKNOWN
Copy Number Variation in CHRNA7 Gene in Migraine and Gene Expression	nan	COMPLETED
The Locus Coeruleus, Norepinephrine and Cognitive Aging	nan	ACTIVE_NOT_RECRUITING
fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia	nan	COMPLETED
Effects of Prazosin on the Attention-Enhancing Effects of Nicotine	nan	WITHDRAWN
Nicotinic Receptor Levels After Stopping Smoking	nan	COMPLETED
Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia	nan	COMPLETED
Brain Receptors in Sympathetic Nervous System Regulation	nan	COMPLETED
Brain Imaging in Alzheimer's Disease	nan	COMPLETED
Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation	nan	RECRUITING
Non-Invasive Brain Stimulation to Improve Language in Down Syndrome.	nan	RECRUITING
Preemptive Oral Gabapentin and Tramadol on Postoperative Pain After Knee Arthroscopy	nan	COMPLETED
The Genetic Characterization of Dementia	nan	COMPLETED
Reversal of Neuromuscular Blockade in Thoracic Surgical Patients	nan	COMPLETED
Brain Tissue Integrity and Autonomic Function Alterations in Childhood OSA and ADHD, and After Adenotonsillectomy.	nan	UNKNOWN
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CHRNB3 binder may also engage these)

Protein	Name	Similarity
Q5IS75	—	1.000	Q5IS75 →
P12391	—	1.000	P12391 →
P43679	—	1.000	P43679 →
Q5IS51	—	1.000	Q5IS51 →
P20420	—	1.000	P20420 →
P26152	—	1.000	P26152 →
Q2MKA5	—	1.000	Q2MKA5 →
CHRNA5	Neuronal acetylcholine receptor subunit alpha	1.000	landscape →
P18257	—	1.000	P18257 →
P02710	—	1.000	P02710 →
Q8SPU7	—	1.000	Q8SPU7 →
Q8R4G9	—	1.000	Q8R4G9 →
P02711	—	1.000	P02711 →
P04757	—	1.000	P04757 →
P49581	—	1.000	P49581 →
CHRNA1	Acetylcholine receptor subunit alpha	1.000	landscape →
P04756	—	1.000	P04756 →
Q07263	—	1.000	Q07263 →
P02709	—	0.999	P02709 →
P09479	—	0.998	P09479 →
P25108	—	0.998	P25108 →
P13908	—	0.998	P13908 →
P43143	—	0.998	P43143 →
O16926	—	0.997	O16926 →
Q9R0W9	—	0.997	Q9R0W9 →
CHRNA6	Neuronal acetylcholine receptor subunit alpha	0.997	landscape →
Q9U298	—	0.997	Q9U298 →
P05377	—	0.996	P05377 →
P04755	—	0.996	P04755 →
Q27218	—	0.996	Q27218 →